KR102822827B1 - 칸디다에 대한 항체 및 이의 용도 - Google Patents

칸디다에 대한 항체 및 이의 용도 Download PDF

Info

Publication number
KR102822827B1
KR102822827B1 KR1020227006350A KR20227006350A KR102822827B1 KR 102822827 B1 KR102822827 B1 KR 102822827B1 KR 1020227006350 A KR1020227006350 A KR 1020227006350A KR 20227006350 A KR20227006350 A KR 20227006350A KR 102822827 B1 KR102822827 B1 KR 102822827B1
Authority
KR
South Korea
Prior art keywords
antibody
delete delete
seq
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227006350A
Other languages
English (en)
Korean (ko)
Other versions
KR20220113346A (ko
Inventor
러셀 비. 윌슨
홍 신
제임스 이. 로빈슨
Original Assignee
더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드
더 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬처럴 앤드 메카니컬 컬리지
스타디우스 바이오파마, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드, 더 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬처럴 앤드 메카니컬 컬리지, 스타디우스 바이오파마, 엘엘씨 filed Critical 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드
Publication of KR20220113346A publication Critical patent/KR20220113346A/ko
Application granted granted Critical
Publication of KR102822827B1 publication Critical patent/KR102822827B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227006350A 2019-07-29 2020-07-28 칸디다에 대한 항체 및 이의 용도 Active KR102822827B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962879894P 2019-07-29 2019-07-29
US201962879912P 2019-07-29 2019-07-29
US62/879,894 2019-07-29
US62/879,912 2019-07-29
PCT/US2020/043908 WO2021021830A1 (en) 2019-07-29 2020-07-28 Antibodies to candida and uses thereof

Publications (2)

Publication Number Publication Date
KR20220113346A KR20220113346A (ko) 2022-08-12
KR102822827B1 true KR102822827B1 (ko) 2025-06-19

Family

ID=74230808

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006350A Active KR102822827B1 (ko) 2019-07-29 2020-07-28 칸디다에 대한 항체 및 이의 용도

Country Status (8)

Country Link
US (1) US20220280618A1 (https=)
EP (1) EP4007772A4 (https=)
JP (1) JP7667773B2 (https=)
KR (1) KR102822827B1 (https=)
CN (1) CN114901688A (https=)
AU (1) AU2020323925A1 (https=)
CA (1) CA3146123A1 (https=)
WO (1) WO2021021830A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991752B (zh) * 2022-12-07 2025-10-31 中国科学技术大学 特定组氨酸甲基化修饰的pra1蛋白免疫原、多克隆抗体及应用
WO2025090760A1 (en) * 2023-10-25 2025-05-01 Board Of Regents, The University Of Texas System Antibodies specific to scube3 and methods of use
CN119930808B (zh) * 2025-01-09 2025-11-25 普健生物（武汉）科技有限公司 一种抗白念珠菌Csa2蛋白的单克隆抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
WO2017009442A1 (en) 2015-07-15 2017-01-19 Genmab A/S Humanized or chimeric cd3 antibodies
US20170137476A1 (en) 2014-06-25 2017-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chimeric Vaccine Against Fungal Infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2651575B2 (ja) * 1987-07-13 1997-09-10 神鋼電機株式会社 インバータの過電流検出装置
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
GB0505489D0 (en) * 2005-03-18 2005-04-20 Domantis Ltd Antibodies
EP2699257A4 (en) 2011-04-21 2014-10-15 Univ Louisiana State PEPTIDE AND CONJUGATE VACCINES FOR FUNGI INFECTIONS
EP3277707A4 (en) * 2015-04-01 2018-08-08 Taipei Medical University Antibodies against infectious diseases
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
US20170137476A1 (en) 2014-06-25 2017-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chimeric Vaccine Against Fungal Infections
WO2017009442A1 (en) 2015-07-15 2017-01-19 Genmab A/S Humanized or chimeric cd3 antibodies

Also Published As

Publication number Publication date
AU2020323925A1 (en) 2022-03-17
KR20220113346A (ko) 2022-08-12
JP2022542699A (ja) 2022-10-06
US20220280618A1 (en) 2022-09-08
EP4007772A4 (en) 2023-11-29
CA3146123A1 (en) 2021-02-04
EP4007772A1 (en) 2022-06-08
JP7667773B2 (ja) 2025-04-23
CN114901688A (zh) 2022-08-12
WO2021021830A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
KR20230028453A (ko) 치료 용도를 위한 ccr8 항체
KR20220140568A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
CN103328513B (zh) 抗ccr4抗体及其应用
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
KR102822827B1 (ko) 칸디다에 대한 항체 및 이의 용도
KR102880907B1 (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
EP4088113A1 (en) Human antibodies to rift valley fever virus
US11299535B2 (en) Human IgE antibodies binding to aspergillus allergens
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
WO2022132887A1 (en) Human monoclonal antibodies targeting the sars-cov-2 spike protein
KR20220103761A (ko) 지카 바이러스를 중화하는 인간 항체 및 이의 사용 방법
US20240288426A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
AU2020273365A1 (en) Human antibodies to Ross River virus and methods of use therefor
CN121729618A (zh) 针对乙型流感病毒的广泛反应性抗体
EA049454B1 (ru) ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К КОРОНАВИРУСУ ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА 2 (SARS-CoV-2)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220224

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220721

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240521

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250529

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250616

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250617

End annual number: 3

Start annual number: 1

PG1601 Publication of registration